» Articles » PMID: 33424583

Does Diet Have a Role in the Treatment of Alzheimer's Disease?

Overview
Specialty Geriatrics
Date 2021 Jan 11
PMID 33424583
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The aging process causes many changes to the brain and is a major risk factor for the development of neurodegenerative diseases such as Alzheimer's Disease (AD). Despite an already vast amount of research on AD, a greater understanding of the disease's pathology and therapeutic options are desperately needed. One important distinction that is also in need of further study is the ability to distinguish changes to the brain observed in early stages of AD vs. changes that occur with normal aging. Current FDA-approved therapeutic options for AD patients have proven to be ineffective and indicate the need for alternative therapies. Aging interventions including alterations in diet (such as caloric restriction, fasting, or methionine restriction) have been shown to be effective in mediating increased health and lifespan in mice and other model organisms. Because aging is the greatest risk factor for the development of neurodegenerative diseases, certain dietary interventions should be explored as they have the potential to act as a future treatment option for AD patients.

Citing Articles

Effects of Caloric Restriction and Intermittent Fasting and Their Combined Exercise on Cognitive Functioning: A Review.

Wang J, Rang Y, Liu C Curr Nutr Rep. 2024; 13(4):691-700.

PMID: 39240488 DOI: 10.1007/s13668-024-00570-8.


Converged avenues: depression and Alzheimer's disease- shared pathophysiology and novel therapeutics.

Bajaj S, Mahesh R Mol Biol Rep. 2024; 51(1):225.

PMID: 38281208 DOI: 10.1007/s11033-023-09170-1.


A Potential Role for the Ketogenic Diet in Alzheimer's Disease Treatment: Exploring Pre-Clinical and Clinical Evidence.

Oliveira T, Morais A, Dos Reis P, Palotas A, Vieira L Metabolites. 2024; 14(1).

PMID: 38248828 PMC: 10818526. DOI: 10.3390/metabo14010025.


Alzheimer's Disease-like Pathological Features in the Dorsal Hippocampus of Wild-Type Rats Subjected to Methionine-Diet-Evoked Mild Hyperhomocysteinaemia.

Kovalska M, Hnilicova P, Kalenska D, Adamkov M, Kovalska L, Lehotsky J Cells. 2023; 12(16).

PMID: 37626897 PMC: 10453870. DOI: 10.3390/cells12162087.


Medium-chain triglycerides may improve memory in non-demented older adults: a systematic review of randomized controlled trials.

Giannos P, Prokopidis K, Lidoriki I, Triantafyllidis K, Kechagias K, Celoch K BMC Geriatr. 2022; 22(1):817.

PMID: 36273115 PMC: 9588230. DOI: 10.1186/s12877-022-03521-6.


References
1.
He N, Jin W, Lok K, Wang Y, Yin M, Wang Z . Amyloid-β(1-42) oligomer accelerates senescence in adult hippocampal neural stem/progenitor cells via formylpeptide receptor 2. Cell Death Dis. 2013; 4:e924. PMC: 3847315. DOI: 10.1038/cddis.2013.437. View

2.
Papadopoli D, Boulay K, Kazak L, Pollak M, Mallette F, Topisirovic I . mTOR as a central regulator of lifespan and aging. F1000Res. 2019; 8. PMC: 6611156. DOI: 10.12688/f1000research.17196.1. View

3.
Presecki P, Muck-Seler D, Mimica N, Pivac N, Mustapic M, Stipcevic T . Serum lipid levels in patients with Alzheimer's disease. Coll Antropol. 2011; 35 Suppl 1:115-20. View

4.
McGrattan A, McGuinness B, McKinley M, Kee F, Passmore P, Woodside J . Diet and Inflammation in Cognitive Ageing and Alzheimer's Disease. Curr Nutr Rep. 2019; 8(2):53-65. PMC: 6486891. DOI: 10.1007/s13668-019-0271-4. View

5.
Koseoglu E . New treatment modalities in Alzheimer's disease. World J Clin Cases. 2019; 7(14):1764-1774. PMC: 6692264. DOI: 10.12998/wjcc.v7.i14.1764. View